+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Middle East & Africa IVF (in-vitro fertilization) Market Outlook, 2029

  • PDF Icon

    Report

  • 68 Pages
  • May 2024
  • Region: Africa, Middle East
  • Bonafide Research
  • ID: 5978374
10% Free customization
1h Free Analyst Time
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The assisted reproductive technology (ART) market in the Middle East & Africa is a vibrant, quickly changing environment. This region is made up of a wide range of nations with different healthcare systems, social mores, and legal systems, all of which have an impact on how IVF services are provided and used. The IVF market in the Middle East & Africa has grown significantly in the last several years due to a number of important factors. First, the demand for IVF treatments has increased throughout the region due to shifting societal patterns, such as postponing childbearing, rising infertility rates, and more knowledge of fertility treatment choices.

Improvements in laboratory procedures, embryo culture techniques, and genetic screening technologies, among other medical technology advances, have raised the success and effectiveness of in vitro fertilisation (IVF) treatments and drawn more patients seeking fertility care. IVF services have also expanded throughout the Middle East & Africa as a result of government programmes and infrastructural investments in the medical field. Following the construction of specialised fertility clinics, ART centres, and research institutions, nations like the United Arab Emirates, Saudi Arabia, and South Africa have become important hubs for IVF therapy.

Patients from surrounding nations are travelling to these healthcare destinations to seek out top-notch IVF services, which has increased access to fertility care and encouraged medical tourism. That being said, there are obstacles in the way of the Middle East & Africa IVF market's expansion. Healthcare inequities, legal and regulatory complexity, economic restraints, and barriers based on culture and religion are a few of them. The infertility care industry in the Middle East & Africa offers prospects as well as difficulties for participants.

The region can continue to advance the delivery of high-quality, accessible IVF services and improve outcomes for individuals and couples looking to start a family through assisted reproduction by taking into account the specific needs and preferences of their patients, utilizing technological advancements, and encouraging collaboration between the public and private sectors.

According to the research report, the Middle East & Africa IVF market is anticipated to add to more than USD 0.6 Billion by 2024-29. Many variables that have changed the landscape of assisted reproductive technology (ART) in the Middle East & Africa have contributed to the market's noteworthy expansion in recent years. The rising need for reproductive treatments among single people and couples is one important factor driving this expansion. The number of patients requesting IVF services in the area has increased as a result of factors such postponed childbirth, rising infertility rates, and increased knowledge of available choices for conception help.

Furthermore, improvements in IVF processes, lab procedures, and genetic screening techniques, among other medical technology advancements, have raised success rates and broadened the range of treatment alternatives accessible to patients. In addition, government funding and infrastructure developments in the medical field have been major factors in the expansion of the IVF market in the Middle East & Africa. Reproductive health has been given top priority in the region's countries' healthcare agendas, which has resulted in the development of specialised fertility clinics, ART centres, and research facilities.

As a result of the better availability to IVF procedures and the growth of medical tourism, patients from nearby nations are seeking advanced reproductive treatments in the region's medical centres. Moreover, the Middle East & Africa's IVF industry has grown as a result of shifting cultural norms and views around family planning and reproductive health. IVF services are in high demand as more people and couples become willing to consider infertility treatment choices. This mentality change, together with rising disposable incomes and urbanisation patterns, has made the conditions ideal for the IVF industry to grow throughout the region.

In general, the IVF market in the Middle East & Africa is expanding steadily because to factors like rising demand, advancing technology, government backing, and changing social perceptions. Opportunities for additional growth and innovation in reproductive care are anticipated to arise as the region continues to develop economically and technologically, influencing the future landscape of ART in the Middle East & Africa.

Major Drivers:

  • Innovative Treatment Modalities: Ongoing research and development efforts in the field of reproductive medicine lead to the introduction of innovative treatment modalities and technologies, including mitochondrial replacement therapy (MRT), endometrial receptivity assays, and artificial intelligence (AI) applications in embryo selection. These advancements improve treatment outcomes, expand treatment options, and drive market growth by offering cutting-edge solutions to patients with complex fertility challenges.
  • Medical Education and Training: The growing demand for fertility treatments in the Middle East & Africa has spurred investments in medical education and training programs for healthcare professionals specializing in reproductive medicine and assisted reproductive technologies. Initiatives aimed at enhancing the skills and knowledge of fertility specialists, embryologists, and nurses contribute to the provision of high-quality IVF services and improved patient outcome.

Major challenges:

  • Data Privacy and Confidentiality: Protecting patient privacy and confidentiality in the collection, storage, and sharing of sensitive medical information is paramount in the IVF market. Challenges related to data privacy laws, cybersecurity threats, and information breaches may arise, particularly in regions with evolving regulatory landscapes and limited enforcement mechanisms. Strengthening data protection policies, implementing secure information systems, and promoting ethical practices in data management can safeguard patient privacy and uphold trust in IVF services.
  • Long-term Follow-up and Support: Providing long-term follow-up and support for patients after IVF treatment is crucial for monitoring outcomes, addressing post-treatment concerns, and supporting ongoing reproductive health needs. Challenges such as continuity of care, access to fertility preservation options, and psychological support for patients experiencing treatment failures or pregnancy losses may arise. Developing comprehensive follow-up programs, survivorship care plans, and patient support networks can enhance the continuity of care and improve the overall patient experience in the IVF market.

Major Trends:

  • Focus on Wellness and Holistic Support Services: there is a growing emphasis on holistic support services and wellness initiatives in the Middle East & Africa IVF market, aimed at addressing the psychosocial, emotional, and nutritional needs of patients undergoing fertility treatments. Integrative approaches incorporating acupuncture, mindfulness practices, nutrition counseling, and stress management techniques complement conventional IVF protocols, promote overall well-being, and enhance treatment outcomes.
  • Patient Advocacy and Empowerment: Patient advocacy organizations and support groups are playing an increasingly influential role in the Middle East & Africa IVF market, advocating for patient rights, raising awareness about infertility issues, and providing emotional support to individuals and couples undergoing fertility treatments. Patient-centered advocacy initiatives empower patients to voice their concerns, navigate treatment options, and access resources to make informed decisions about their reproductive health. Patient advocacy efforts contribute to greater transparency, accountability, and patient-centered care in the IVF market.
As cryopreservation techniques continue to advance and become more widely accessible, the utilization of frozen donor IVF cycles is expected to further increase, contributing to the continued growth and evolution of the IVF market.

The importance of frozen donor IVF cycles as a noteworthy and developing category is highlighted by a segmentation analysis of the IVF market by cycle. By enabling the preservation of donor embryos or oocytes for later use, developments in cryopreservation techniques have transformed the field of assisted reproduction in recent years. Since cryopreserved embryos or oocytes can be kept for extended periods of time until the recipient is ready to continue with the cycle, this method gives patients a flexible and convenient choice for undertaking IVF therapy. One of the key advantages of frozen donor IVF cycles is the enhanced success rates compared to fresh donor cycles.

Cryopreservation techniques, such as verification, have significantly improved the survival rates of frozen embryos and oocytes, leading to higher implantation and pregnancy rates. Additionally, frozen donor IVF cycles eliminate the need for synchronizing the recipient's cycle with that of the donor, streamlining the treatment process and reducing waiting times for patients. Further, by reducing the dangers connected with ovarian stimulation, frozen donor IVF cycles provide a safer option than conventional fresh donor cycles.

Patients can get therapy with better comfort and confidence when they do not require ovarian stimulation, which spares them from the possible risks of ovarian hyper stimulation syndrome (OHSS). Additionally, the likelihood of a successful implantation and pregnancy is increased by timing the embryo transfer according to the recipient's menstrual cycle and uterine receptivity.

The choice between conventional IVF and IVF with ICSI depends on various factors, including the underlying cause of infertility, sperm quality, previous treatment outcomes, and clinician recommendations


Patients undergoing assisted reproduction have different preferences and treatment methods, according to a segmentation analysis of the IVF market by traditional IVF and IVF with ICSI (Intracytoplasmic Sperm Injection). In a typical IVF procedure, sperm naturally pierces the outer layer of the egg to fertilize it while fertilizing eggs in a lab dish. This method works well for couples whose sperm motility and quality are sufficient for fertilisation but whose male factor infertility is modest to moderate. Conversely, IVF with ICSI is a specialised method used in cases of more severe male factor infertility, which is defined by low sperm count, poor motility, or aberrant morphology of sperm.

Removing the need for sperm to pass through the egg's outer layer, the ICSI involves selecting a single sperm and injecting it straight into the cytoplasm of the egg using a micropipette. This accurate sperm injection technique guarantees fertilisation even in situations where the quality of the sperm is significantly reduced, making it a very successful alternative for couples dealing with male infertility problems.

The decision between IVF with ICSI and conventional IVF is influenced by a number of variables, such as the sperm quality, prior treatment results, and doctor recommendations. IVF with ICSI provides a solution in situations where conventional IVF might not be able to successfully fertilize a child, even though conventional IVF might be adequate for couples with mild male factor infertility or when there is no male component present.

Hospitals and surgical centers play a critical role in addressing the unique needs of diverse patient populations seeking fertility treatment


The important role that hospitals and surgical centres play in providing fertility treatments and assisted reproductive services is revealed by segmenting the IVF market by end-user. These organisations function as important centres for providing all-inclusive infertility care, providing individuals and couples in need of reproductive support with a broad range of diagnostic, therapeutic, and surgical options. With cutting-edge reproductive laboratories, operating rooms, and fertility clinics manned by multidisciplinary teams of reproductive endocrinologists, embryologists, urologists, and specialised nursing personnel, hospitals and surgical centres are outfitted with cutting-edge facilities.

In addressing the male and female components that contribute to reproductive difficulties, this integrated approach enables the thorough evaluation and management of infertility disorders. Patients can access the entire range of reproductive services offered by hospital-based IVF programmes, such as IVF, intrauterine insemination (IUI), ovulation induction, intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and embryo transfer procedures. For the diagnosis and treatment of diseases including endometriosis, uterine fibroids, and tubal factor infertility, surgical centres inside hospitals also provide minimally invasive surgical techniques like laparoscopy and hysteroscopy.

In addition to giving counseling services, support groups, and patient education programmes to address the emotional and psychological elements of infertility, hospitals and surgical centres offer a caring and supportive environment for individuals undergoing reproductive therapy. In order to promote general well-being and resilience among people and couples navigating the obstacles of infertility, this holistic approach to care emphasizes the significance of patient-centered support and advocacy throughout the IVF experience.

In Middle East & Africa, the IVF market is characterized by a mature and well-established healthcare infrastructure, robust regulatory frameworks, and high levels of consumer awareness and acceptance of fertility treatments


The comprehension of the geographic distribution, trends, and dynamics influencing the assisted reproductive technologies landscape in various locations can be gained by a regional analysis of the IVF market. Variations in market size, growth rates, and treatment preferences are caused by the distinct demographic, cultural, legislative, and economic elements that are present in each region and impact the delivery of fertility treatments as well as the demand for them. The area is home to a large number of university medical facilities, specialty reproductive clinics, and fertility clinics that provide a wide range of assisted reproductive technologies, such as IVF, ICSI, PGT, and egg freezing.

The IVF market in Europe varies greatly between nations and areas, which is indicative of differences in healthcare systems, cultural perspectives on fertility, and legal frameworks pertaining to assisted reproduction. Nations like the Czech Republic, Denmark, and Spain are becoming well-liked travel destinations for medical tourism, drawing clients from all over the world looking for excellent, reasonably priced reproductive care. Continuous improvements in IVF methods, research partnerships, and international reproductive health programmes are observed in the region, spurring innovation and knowledge sharing in the field. Harmonized regulatory standards and fair healthcare access across Europe are necessary to address the issues posed by ethical discussions.

Years considered in this report:

  • Historic year: 2018
  • Base year: 2023
  • Estimated year: 2024
  • Forecast year: 2029

Aspects covered in the report:

  • IVF market Outlook with its value and forecast along with its segments
  • Various drivers and challenges
  • On-going trends and developments
  • Top profiled companies
  • Strategic recommendations

By cycle:

  • Fresh Non-donor IVF Cycle
  • Frozen Non-donor IVF Cycle
  • Frozen donor IVF Cycle
  • Fresh donor IVF Cycle

By Conventional IVF:

  • Conventional IVF
  • IVF with ICSI (Instracytoplasmic Sperm Injection)
  • IVF With Donor Eggs
  • other

By End user:

  • Fertility Clinics
  • Hospital & Surgical Centers
  • Cryobanks
  • Research institute

The approach of the report:

This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases.

After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. After this, the analysts made primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once they acquired the primary data, they started verifying the details obtained from secondary sources.

Intended audience:

This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the IVF industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.

Table of Contents

1. Executive Summary
2. Research Methodology
2.1. Secondary Research
2.2. Primary Data Collection
2.3. Market Formation & Validation
2.4. Report Writing, Quality Check & Delivery
3. Market Structure
3.1. Market Considerate
3.2. Assumptions
3.3. Limitations
3.4. Abbreviations
3.5. Sources
3.6. Definitions
4. Economic/Demographic Snapshot
5. Global In Vitro Fertilization Market Outlook
5.1. Market Size by Value
5.2. Market Share by Region
5.3. Market Size and Forecast, by Cycle
5.4. Market Size and Forecast, by Conentional IVF
5.5. Market Size and Forecast, by End user
6. Middle East & Africa In Vitro Fertilization Market Outlook
6.1. Market Size by Value
6.2. Market Share by Country
6.3. Market Size and Forecast, by Cycle
6.4. Market Size and Forecast, by Conentional IVF
6.5. Market Size and Forecast, by End user
7. Market Dynamics
7.1. Market Drivers & Opportunities
7.2. Market Restraints & Challenges
7.3. Market Trends
7.4. COVID-19 Effect
7.5. Supply Chain Analysis
7.6. Policy & Regulatory Framework
7.7. Industry Experts Views
7.8. UAE In Vitro Fertilization Market Outlook
7.8.1. Market Size by Value
7.8.2. Market Size and Forecast by Cycle
7.8.3. Market Size and Forecast by Conentional IVF
7.8.4. Market Size and Forecast by End user
7.9. Saudi Arabia In Vitro Fertilization Market Outlook
7.9.1. Market Size by Value
7.9.2. Market Size and Forecast by Cycle
7.9.3. Market Size and Forecast by Conentional IVF
7.9.4. Market Size and Forecast by End user
7.10. South Africa In Vitro Fertilization Market Outlook
7.10.1. Market Size by Value
7.10.2. Market Size and Forecast by Cycle
7.10.3. Market Size and Forecast by Conentional IVF
7.10.4. Market Size and Forecast by End user
8. Competitive Landscape
8.1. Competitive Dashboard
8.2. Business Strategies Adopted by Key Players
8.3. Key Players Market Positioning Matrix
8.4. Porter's Five Forces
8.5. Company Profiles
8.5.1. Thermo Fisher Scientific Inc.
8.5.1.1. Company Snapshot
8.5.1.2. Company Overview
8.5.1.3. Financial Highlights
8.5.1.4. Geographic Insights
8.5.1.5. Business Segment & Performance
8.5.1.6. Product Portfolio
8.5.1.7. Key Executives
8.5.1.8. Strategic Moves & Developments
8.5.2. Fujifilm Holdings Corporation
8.5.3. Merck KGaA
8.5.4. The Cooper Companies, Inc.
8.5.5. Esco Micro Pte. Ltd
9. Strategic Recommendations
10. Annexure
10.1. FAQs
10.2. Notes
10.3. Related Reports
11. Disclaimer
List of Figures
Figure 1: Global In Vitro Fertilization Market Size (USD Billion) by Region, 2023 & 2029
Figure 2: Market attractiveness Index, by Region 2029
Figure 3: Market attractiveness Index, by Segment 2029
Figure 4: Global In Vitro Fertilization Market Size by Value (2018, 2023 & 2029F) (in USD Billion)
Figure 5: Global In Vitro Fertilization Market Share by Region (2023)
Figure 6: Middle East & Africa In Vitro Fertilization Market Size by Value (2018, 2023 & 2029F) (in USD Billion)
Figure 7: Middle East & Africa In Vitro Fertilization Market Share by Country (2023)
Figure 8: UAE In Vitro Fertilization Market Size by Value (2018, 2023 & 2029F) (in USD Billion)
Figure 9: Saudi Arabia In Vitro Fertilization Market Size by Value (2018, 2023 & 2029F) (in USD Billion)
Figure 10: South Africa In Vitro Fertilization Market Size by Value (2018, 2023 & 2029F) (in USD Billion)
Figure 11: Competitive Dashboard of top 5 players, 2023
Figure 12: Porter's Five Forces of Global In Vitro Fertilization Market
List of Tables
Table 1: Global In Vitro Fertilization Market Snapshot, by Segmentation (2023 & 2029) (in USD Billion)
Table 2: Top 10 Counties Economic Snapshot 2022
Table 3: Economic Snapshot of Other Prominent Countries 2022
Table 4: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 5: Global In Vitro Fertilization Market Size and Forecast, by Cycle (2018 to 2029F) (In USD Billion)
Table 6: Global In Vitro Fertilization Market Size and Forecast, by Conentional IVF (2018 to 2029F) (In USD Billion)
Table 7: Global In Vitro Fertilization Market Size and Forecast, by End user (2018 to 2029F) (In USD Billion)
Table 8: Middle East & Africa In Vitro Fertilization Market Size and Forecast, by Cycle (2018 to 2029F) (In USD Billion)
Table 9: Middle East & Africa In Vitro Fertilization Market Size and Forecast, by Conentional IVF (2018 to 2029F) (In USD Billion)
Table 10: Middle East & Africa In Vitro Fertilization Market Size and Forecast, by End user (2018 to 2029F) (In USD Billion)
Table 11: Influencing Factors for In Vitro Fertilization Market, 2023
Table 12: United Arab Emirates In Vitro Fertilization Market Size and Forecast by Cycle (2018 to 2029F) (In USD Billion)
Table 13: United Arab Emirates In Vitro Fertilization Market Size and Forecast by Conentional IVF (2018 to 2029F) (In USD Billion)
Table 14: United Arab Emirates In Vitro Fertilization Market Size and Forecast by End user (2018 to 2029F) (In USD Billion)
Table 15: Saudi Arabia In Vitro Fertilization Market Size and Forecast by Cycle (2018 to 2029F) (In USD Billion)
Table 16: Saudi Arabia In Vitro Fertilization Market Size and Forecast by Conentional IVF (2018 to 2029F) (In USD Billion)
Table 17: Saudi Arabia In Vitro Fertilization Market Size and Forecast by End user (2018 to 2029F) (In USD Billion)
Table 18: South Africa In Vitro Fertilization Market Size and Forecast by Cycle (2018 to 2029F) (In USD Billion)
Table 19: South Africa In Vitro Fertilization Market Size and Forecast by Conentional IVF (2018 to 2029F) (In USD Billion)
Table 20: South Africa In Vitro Fertilization Market Size and Forecast by End user (2018 to 2029F) (In USD Billion)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Thermo Fisher Scientific Inc.
  • Fujifilm Holdings Corporation
  • Merck KGaA
  • The Cooper Companies, Inc.
  • Esco Micro Pte. Ltd